THEMISMED NSE filing

Themis Medicare Q2 FY27: Revenue up 15.1% to ₹89.74 Cr, Returns to Profitability

The RealCase readHigh impact Positive

Themis Medicare's Q2 FY27 results show a strong turnaround with revenue up 15.1% YoY to ₹89.74 crore, led by a 71% surge in API business. The company returned to profitability with EBITDA at ₹5.58 crore (6.2% margin) and PAT of ₹7.06 crore. H1 FY27 revenue reached ₹176.70 crore.

Why it matters

The substantial revenue growth, return to profitability after a loss-making period, and positive management commentary on future outlook suggest a significant positive impact on the company's performance and investor sentiment.

The market read

The company reported a significant year-on-year improvement in revenue and a return to profitability, indicating a positive operational and financial performance.

Themis Medicare Limited has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a significant turnaround in Q2 FY27, with revenue growing 15.1% year-on-year to ₹89.74 crore and 3.2% over the previous quarter. This growth was primarily driven by a 71% rebound in the API business to ₹20 crore, while the Formulations business maintained steady performance at ₹69 crore.

The company returned to operating profitability, reporting an EBITDA of ₹5.58 crore with a 6.2% margin, compared to a loss in the year-ago quarter. Profit After Tax (PAT) stood at ₹7.06 crore, a substantial improvement from the loss reported previously. Management attributes this improvement to a focus on productivity and operational efficiency, alongside inventory pricing optimization and cost structure adjustments.

Within the Formulations segment, the Critical Care Division showed steady revenue and doubled its Profit Before Tax (PBT), with Themisal Gel demonstrating positive month-on-month momentum. The Ortho and Gynecology Division doubled its revenue, supported by strong traction in the hormonal portfolio and an integrated product strategy.

The API business showed a strong recovery, with active engagement with overseas customers for new molecules. For the half-year ended September 30, 2026 (H1 FY27), revenue was ₹176.70 crore, with the strong performance in Q2 helping to offset a more challenging first quarter. The company expressed optimism for the second half of the year, driven by continued operational efficiencies, field productivity, disciplined cost management, and the sustained recovery in the API business.

The investor presentation also highlighted the company's strategic focus on enhancing profitability and cash flow through improved clinic effectiveness, targeted doctor outreach, operational efficiencies, and a stronger presence in the Hospital and API businesses. The company aims to achieve a leadership position in India's hospital business and expand into new markets, with plans to enter regulated markets in the EU and USA within 3 to 5 years.

Filing to action

What to do with a filing like this

Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.

View original filing